MiniMed Group (NASDAQ:MMED) Now Covered by Analysts at Barclays

Stock analysts at Barclays initiated coverage on shares of MiniMed Group (NASDAQ:MMED) in a report released on Wednesday,Benzinga reports. The brokerage set an “overweight” rating and a $26.00 price target on the stock. Barclays‘s price objective indicates a potential upside of 81.56% from the stock’s previous close.

A number of other analysts have also weighed in on MMED. William Blair began coverage on shares of MiniMed Group in a research note on Tuesday. They issued an “outperform” rating for the company. Citigroup started coverage on MiniMed Group in a report on Tuesday. They set a “buy” rating and a $23.00 target price on the stock. BTIG Research assumed coverage on MiniMed Group in a research note on Tuesday. They set a “buy” rating and a $25.00 price target for the company. Mizuho assumed coverage on MiniMed Group in a report on Tuesday. They issued an “outperform” rating and a $21.00 price objective for the company. Finally, Piper Sandler began coverage on MiniMed Group in a research note on Tuesday. They set a “neutral” rating and a $16.00 target price for the company. Eleven research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $22.45.

MiniMed Group Trading Down 4.0%

MMED traded down $0.60 on Wednesday, reaching $14.32. The company had a trading volume of 49,144 shares, compared to its average volume of 1,051,994. MiniMed Group has a one year low of $14.10 and a one year high of $20.48.

More MiniMed Group News

Here are the key news stories impacting MiniMed Group this week:

• Positive Sentiment: Bank of America started coverage with a Buy rating and a $27 price target, flagging a pipeline-driven inflection point and implying substantial upside from current levels. MiniMed initiated with ‘Buy’ rating by Bank of America
• Positive Sentiment: Goldman Sachs, Wells Fargo, Citigroup, BTIG, Deutsche Bank, Mizuho, Evercore, Morgan Stanley and William Blair initiated coverage or issued Buy/Outperform/Overweight ratings with price targets generally in the $19–$26 range (several above $20), signaling broad institutional optimism about MiniMed’s standalone growth prospects. Zacks coverage summary
• Neutral Sentiment: Piper Sandler issued a Neutral rating with a $16 target — a more conservative view that suggests limited near-term upside relative to some peers’ forecasts. Piper Sandler initiation summary
• Neutral Sentiment: TipRanks published a note framing MiniMed as a Hold for investors balancing franchise strength versus execution risks, underscoring that upside depends on execution of the pipeline and standalone operating performance. Balancing Franchise Strength with Execution Risks

MiniMed Group Company Profile

We are a scaled global medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. Since our founding more than 40 years ago, we have pioneered groundbreaking innovation and served the needs of our customers across the globe in service of our mission to make every day a better day for people with diabetes. Today, we are the only player in the market that commercializes all parts of an integrated diabetes management system.